IGC PHARMA, INC. Other Significant Noncash Transaction, Value of Consideration Received
IGC PHARMA, INC. (IGC) reported Other Significant Noncash Transaction, Value of Consideration Received of $0 for the 12-month period ending 2018-03-31, per its 10-K filed 2018-06-21.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1 · last filed 2018-06-21
- IGC PHARMA, INC. other significant noncash transaction, value of consideration received for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- IGC PHARMA, INC. other significant noncash transaction, value of consideration received for fiscal 2017 was $1.83M.
| Period end | Other Significant Noncash Transaction, Value of Consideration Received 12 month |
|---|---|
| 2018-03-31 | $0.00 10-K · filed 2018-06-21 |
| 2017-03-31 | $1.83M 10-K · filed 2018-06-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |